VitroScan's ChemoPredict platform aims to identify chemotherapy-resistant and sensitive ovarian cancer patients, enhancing treatment strategies through personalized approaches. With a recent €1.9 million funding boost from Biotech Booster, VitroScan is set to prepare this service for clinical use, meeting vital quality and regulatory standards.
The funding from Biotech Booster, an initiative supporting biotechnology commercialization, not only allows VitroScan to advance their research but ensures a collaboration with experts from both Leiden University Medical Centre and Radboud University Medical Centre, reinforcing the clinical relevance of their offerings.
Biotech Booster is a strategic program established in 2022 to facilitate the transition of biotech discoveries into market applications, with €250 million in subsidies aimed at supporting innovative projects across various clusters within the field.
The connection between academia and industry through programs like Biotech Booster exemplifies a significant shift towards translational medicine, where research findings are rapidly utilized to create practical solutions for patient care, especially in specialized areas like oncology.
Collection
[
|
...
]